Research in Review

Clearance of Somatic Mutations and the Effect on Risk of Relapse in AML

Clearance of somatic mutation at complete remission is associated with significantly better survival in patients with acute myeloid leukemia.

Read More


AML Immune Profile Linked With Relapse-Free Survival

Texas Oncology, Aetna Collaborate to Improve Patient Care Through Clinical Pathways

Texas Oncology and Aetna partnered to provide a practice-based program that reduced costs while maintaining adherence to treatment pathways and patient satisfaction in Medicare patients.

Read More


ASCO Releases Review of Prominent Commercial Clinical Pathway Vendors

The American Society of Clinical Oncology Task Force assessed 6 national pathway vendors to compare their products against the ASCO Criteria for High-Quality Clinical Pathways.

Read More


Real-World Outcomes of Patients With NSCLC Treated With PD-1 Inhibitors After Approval

Certain subgroups of patients with NSCLC are underrepresented in clinical trials for newly approved PD-1 inhibitors and are needed to inform real-world treatment decisions.

Read More


Multiple Myeloma, Lymphoma Respond Differently to Treatment for Anemia

A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma.

Read More


Health Care Utilization High for Hospitalized Patients With Advanced Cancer

Clinical Pathways for Myeloid Growth Factors Lead to Appropriate Use

A poster presentation at AMCP Nexus 2017 found that the implementation of a clinical pathway increased the appropriate use of myeloid growth factors for patients receiving myelosuppressive cancer chemotherapy.

Read More


High Risk of Preventable and Mitigable Adverse Events in Cancer Care

Researchers have identified a significant burden of adverse events across the cancer care continuum, including preventable or mitigable events.

Read More


Patients with mantle cell lymphoma should be stratified based on the status of a specific mutation and considered for alternative first-line therapy.
A recent study uncovered the benefits of adding high-intensity local treatment to systemic therapy for head and neck squamous cell carcinoma.
A recent study compared the treatment effects and adverse events of first-line chemotherapy regimens in patients with treatment-naïve DLBCL.